EXPLORINEER
en

Archive — US — turtlesai

Onc.AI Introduces New AI Model to Improve Survival Assessment in NSCLC Patients

Onc.AI unveiled the Serial CTRS AI model at AACR 2025, enhancing survival predictions in advanced NSCLC patients. It has gained FDA Breakthrough Device Designation, showing improved accuracy over traditional methods, including RECIST 1.1. The model was developed in collaboration with GSK and Flatiron Health, marking a significant advancement in AI-assisted cancer treatment assessment.

Key points

  • Onc.AI presented the Serial CTRS model at AACR 2025, showing improved survival prediction for advanced NSCLC patients.
  • The model was evaluated in Cohort E of GSK’s Phase 1 GARNET clinical trial with patients treated with dostarlimab.
  • Serial CTRS received Breakthrough Device Designation from the FDA for its potential to enhance outcomes for NSCLC patients.
  • The model outperformed traditional methods like RECIST 1.1 in predicting overall survival using routine CT imaging without manual annotations.
  • Collaboration with Flatiron Health contributed high-quality real-world data to the model's development, enhancing its accuracy and reliability.

Why it matters

  • The introduction of AI in oncology follows a growing trend of utilizing machine learning to improve clinical decision-making.
  • In 2025, significant advancements in AI technology are transforming cancer treatment assessments, echoing previous trends in digital health and personalized medicine.
  • The FDA's Breakthrough Device Designation is part of a broader regulatory trend to expedite innovation in medical technologies, supporting enhanced patient outcomes.

The Serial CTRS model by Onc.AI symbolizes a pivotal shift in using AI for cancer prognosis, improving survival assessments for NSCLC and supporting oncologists in making data-driven treatment decisions.